AGIOS PHARMACEUTICALS, INC.
About AGIOS PHARMACEUTICALS, INC.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $54.0M
- Net income
- -$412.8M
- Total assets
- $1.3B
- Market cap
- $1.7B
- Gross margin
- 88.3%
- Operating margin
- -873.9%
- Net margin
- -764.0%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $54.0M
- Cost of revenue
- $6.3M
- Gross profit
- $47.7M
- Operating expenses
- $519.8M
- Operating income
- -$472.1M
- Income tax
- -$1.0M
- Net income
- -$412.8M
- EPS (basic)
- $-7.12
- EPS (diluted)
- $-7.12
Balance sheet
- Total assets
- $1.3B
- Current assets
- $942.1M
- Total liabilities
- $104.1M
- Current liabilities
- $82.2M
- Shareholders’ equity
- $1.2B
Cash flow
- Operating cash flow
- -$373.0M
- Investing cash flow
- $377.2M
- Financing cash flow
- $8.7M
- Net cash flow
- $12.9M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.7B
- EPS (diluted)
- $-7.12
- Shares outstanding
- 58.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 24, 2013
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $412.8M in FY2025.
- Gross margin of 88.3%, net margin -764.0%.
- Trading 37% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review AGIOS PHARMACEUTICALS, INC..
Write a review
News about AGIOS PHARMACEUTICALS, INC.
News & sentiment via Polygon.io
